Natural innate and adaptive immunity to cancer.

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02

Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43

Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23

Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66

Origins of metastatic traits. Cancer Cell (2013) 2.49

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47

Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30

Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell (2016) 2.24

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14

Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 2.13

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09

Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90

The extracellular matrix modulates the hallmarks of cancer. EMBO Rep (2014) 1.88

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature (2015) 1.87

Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77

A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov (2012) 1.77

Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76

Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol (2013) 1.70

Targeting regulatory T cells in cancer. Cancer Res (2011) 1.66

Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology (2014) 1.60

Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell (2012) 1.54

Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment. Mol Cancer (2016) 1.51

An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell (2017) 1.49

Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38

Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell (2016) 1.36

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci (2013) 1.34

Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) (2013) 1.33

Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.32

High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology (2012) 1.28

Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 1.27

The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23

Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol (2013) 1.22

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut (2012) 1.22

Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol (2013) 1.20

Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol (2013) 1.20

Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology (2012) 1.20

Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 1.19

Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol (2011) 1.17

Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer (2013) 1.15

Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model. Bioessays (2014) 1.13

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One (2011) 1.12

Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12

The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11

HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol (2012) 1.10

Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS One (2012) 1.09

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2014) 1.08

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res (2014) 1.08

Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A (2015) 1.08

The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07

Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med (2013) 1.07

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res (2012) 1.06

The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) (2015) 1.06

The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J Exp Med (2013) 1.06

Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem (2013) 1.06

Chemokines in cancer. Cancer Immunol Res (2014) 1.03

IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One (2012) 1.01

Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00

Chemopreventive properties of dietary rice bran: current status and future prospects. Adv Nutr (2012) 1.00

Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99

Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99

Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med (2013) 0.99

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol (2012) 0.98

Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer (2013) 0.98

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98

Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles (2013) 0.97

Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 0.97

Epigenetic regulation of NK cell differentiation and effector functions. Front Immunol (2013) 0.96

Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One (2013) 0.96

Immune modulation during latent herpesvirus infection. Immunol Rev (2012) 0.96

Advances in high-throughput single-cell microtechnologies. Curr Opin Biotechnol (2013) 0.95

Why are epididymal tumours so rare? Asian J Androl (2012) 0.95

Immune system: a double-edged sword in cancer. Inflamm Res (2013) 0.95

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology (2014) 0.95

Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways. Front Genet (2013) 0.94

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis (2014) 0.94

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget (2016) 0.93

The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med (2016) 0.93

Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. Oncoimmunology (2013) 0.93

Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol (2014) 0.93

Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer (2013) 0.93

The new deal: a potential role for secreted vesicles in innate immunity and tumor progression. Front Immunol (2015) 0.93

Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res (2013) 0.93

Mechanisms Underlying Latent Disease Risk Associated with Early-Life Arsenic Exposure: Current Research Trends and Scientific Gaps. Environ Health Perspect (2015) 0.93

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92

Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology (2012) 0.92

3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro. Adv Healthc Mater (2012) 0.92

Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res (2012) 0.92

The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila) (2013) 0.92

Pancreatic cancer, inflammation, and microbiome. Cancer J (2014) 0.91

Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 0.91

Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol (2013) 0.91

Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther (2015) 0.91

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75

The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39

Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23

The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20

Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14

Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87

NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44

Immune surveillance of tumors. J Clin Invest (2007) 5.04

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98

Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol (2006) 4.87

IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65

CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48

The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18

A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14

IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04

Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96

Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet (2003) 3.95

Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64

The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23

Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20

Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19

A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13

Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04

IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99

A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88

Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83

Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77

A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73

BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62

Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59

Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57

Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res (2006) 2.56

Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54

Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48

Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol (2007) 2.43

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30

NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26

Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature (2012) 2.25

Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21

The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med (2003) 2.20

Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol (2008) 2.19

Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10

Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09

Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08

Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol (2007) 2.05

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04

CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03

Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest (2003) 2.02

Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol (2005) 2.01

IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00

Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet (2005) 1.99

CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity (2011) 1.99

Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97

Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95

Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94

Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93

Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91

DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature (2008) 1.88

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88

Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83

TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82

The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82

Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res (2005) 1.75

Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet (2006) 1.74

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73

Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity (2009) 1.73

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res (2010) 1.71